Research in the Field of Drug Design and Development

J 2023

Research in the Field of Drug Design and Development

BIALA, Grazyna, Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN et. al.

Základní údaje

Originální název

Research in the Field of Drug Design and Development

Autoři

BIALA, Grazyna (garant), Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN, Aleksandra SKROK, Jakub KAMINSKI, Eva HAVRÁNKOVÁ (203 Česká republika, domácí), Dominika NADASKA a Ivan MALIK

Vydání

Pharmaceuticals, BASEL, MDPI, 2023, 1424-8247

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30104 Pharmacology and pharmacy

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 4.600 v roce 2022

Kód RIV

RIV/00216224:14160/23:00132055

Organizační jednotka

Farmaceutická fakulta

DOI

http://dx.doi.org/10.3390/ph16091283

UT WoS

001074283700001

Klíčová slova anglicky

drug discovery; drug synthesis; in vivo studies; in vitro studies; clinical trials

Štítky

rivok, ÚChL

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 27. 10. 2023 15:29, JUDr. Sabina Krejčiříková

Anotace

V originále

The processes used by academic and industrial scientists to discover new drugs have recently experienced a true renaissance, with many new and exciting techniques being developed over the past 5-10 years alone. Drug design and discovery, and the search for new safe and well-tolerated compounds, as well as the ineffectiveness of existing therapies, and society's insufficient knowledge concerning the prophylactics and pharmacotherapy of the most common diseases today, comprise a serious challenge. This can influence not only the quality of human life, but also the health of whole societies, which became evident during the COVID-19 pandemic. In general, the process of drug development consists of three main stages: drug discovery, preclinical development using cell-based and animal models/tests, clinical trials on humans and, finally, forward moving toward the step of obtaining regulatory approval, in order to market the potential drug. In this review, we will attempt to outline the first three most important consecutive phases in drug design and development, based on the experience of three cooperating and complementary academic centers of the Visegrad group; i.e., Medical University of Lublin, Poland, Masaryk University of Brno, Czech Republic, and Comenius University Bratislava, Slovak Republic.

Citovat

BIALA, Grazyna, Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN, Aleksandra SKROK, Jakub KAMINSKI, Eva HAVRÁNKOVÁ, Dominika NADASKA a Ivan MALIK. Research in the Field of Drug Design and Development. Pharmaceuticals. BASEL: MDPI, 2023, roč. 16, č. 9, s. 1-23. ISSN 1424-8247. Dostupné z: https://dx.doi.org/10.3390/ph16091283.

@article{2330845,
   author = {Biala, Grazyna and Kedzierska, Ewa and KrukandSlomka, Marta and OrzelskaandGorka, Jolanta and Hmaidan, Sara and Skrok, Aleksandra and Kaminski, Jakub and Havránková, Eva and Nadaska, Dominika and Malik, Ivan},
   article_location = {BASEL},
   article_number = {9},
   doi = {http://dx.doi.org/10.3390/ph16091283},
   keywords = {drug discovery; drug synthesis; in vivo studies; in vitro studies; clinical trials},
   language = {eng},
   issn = {1424-8247},
   journal = {Pharmaceuticals},
   title = {Research in the Field of Drug Design and Development},
   url = {https://www.mdpi.com/1424-8247/16/9/1283},
   volume = {16},
   year = {2023}
}

TY  - JOUR
ID  - 2330845
AU  - Biala, Grazyna - Kedzierska, Ewa - Kruk-Slomka, Marta - Orzelska-Gorka, Jolanta - Hmaidan, Sara - Skrok, Aleksandra - Kaminski, Jakub - Havránková, Eva - Nadaska, Dominika - Malik, Ivan
PY  - 2023
TI  - Research in the Field of Drug Design and Development
JF  - Pharmaceuticals
VL  - 16
IS  - 9
SP  - 1-23
EP  - 1-23
PB  - MDPI
SN  - 14248247
KW  - drug discovery
KW  - drug synthesis
KW  - in vivo studies
KW  - in vitro studies
KW  - clinical trials
UR  - https://www.mdpi.com/1424-8247/16/9/1283
N2  - The processes used by academic and industrial scientists to discover new drugs have recently experienced a true renaissance, with many new and exciting techniques being developed over the past 5-10 years alone. Drug design and discovery, and the search for new safe and well-tolerated compounds, as well as the ineffectiveness of existing therapies, and society's insufficient knowledge concerning the prophylactics and pharmacotherapy of the most common diseases today, comprise a serious challenge. This can influence not only the quality of human life, but also the health of whole societies, which became evident during the COVID-19 pandemic. In general, the process of drug development consists of three main stages: drug discovery, preclinical development using cell-based and animal models/tests, clinical trials on humans and, finally, forward moving toward the step of obtaining regulatory approval, in order to market the potential drug. In this review, we will attempt to outline the first three most important consecutive phases in drug design and development, based on the experience of three cooperating and complementary academic centers of the Visegrad group; i.e., Medical University of Lublin, Poland, Masaryk University of Brno, Czech Republic, and Comenius University Bratislava, Slovak Republic.
ER  -

BIALA, Grazyna, Ewa KEDZIERSKA, Marta KRUK-SLOMKA, Jolanta ORZELSKA-GORKA, Sara HMAIDAN, Aleksandra SKROK, Jakub KAMINSKI, Eva HAVRÁNKOVÁ, Dominika NADASKA a Ivan MALIK. Research in the Field of Drug Design and Development. \textit{Pharmaceuticals}. BASEL: MDPI, 2023, roč.~16, č.~9, s.~1-23. ISSN~1424-8247. Dostupné z: https://dx.doi.org/10.3390/ph16091283.

Podrobný výpis o publikaci